Introduction
Pulmonary hypertension (PH) is common in severe symptomatic left-sided valvular disease, particularly in aging populations, and is usually associated with increased morbidity and mortality. In patients with severe aortic stenosis (AS), PH reflects long-standing stenosis, leading to left ventricular (LV) diastolic dysfunction. The prevalence of PH in patients with AS varies significantly according to the severity of the stenosis, the presence of symptoms and the pressure cut-off used to define PH, ranging from 15% to 30%. 1, 2 Age-related changes in the structure of the heart [LV hypertrophy, left atrial (LA) dilatation and increased fibrosis] in conjunction with impaired LV systolic function, concomitant mitral regurgitation, and increased LV enddiastolic pressure may explain PH in AS. 3 Inconsistent results have been reported for the association between PH and adverse outcomes of AS. [4] [5] [6] [7] [8] Some studies failed to show an independent impact of preoperative pulmonary pressure on postoperative outcome, whereas other series suggested that preoperative PH is associated with increased operative mortality and decreased long-term survival, particularly in the case of severe PH. [5] [6] [7] [8] Moreover, in some studies, PH was defined by echocardiographic estimates of pulmonary artery systolic pressure, which not reliable in some patients because of inaccuracies of right atrial pressure estimation and amplification of measurement errors by using derived variables. 9 Accordingly, recent European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines. 10 recommend using continuous wave Doppler to provide a simple measurement of peak tricuspid regurgitation velocity (TRV) as the main reliable variable for assigning the echocardiographic probability of PH. 10 We therefore investigated the prognostic significance of PH, as proposed by the current ESC/ERS guidelines, 10 in a large cohort of patients with severe AS, in the context of routine clinical practice. > _50% were prospectively identified and included in an electronic database. 11 The following patients were excluded: (i) patients with more than mild aortic and/or mitral regurgitation; (ii) patients with prosthetic valves, congenital heart disease, supravalvular, or subvalvular AS, or dynamic left ventricular outflow tract obstruction; (iii) patients with severe tricuspid regurgitation (TR); and (iv) patients who refused to participate in the study. A total of 1290 patients were enrolled (1046 from Amiens and 244 from Lille). Two hundred seventy one patients with no tricuspid regurgitation or without adequate Doppler signal of peak TRV were subsequently excluded. The final study group consisted of 1019 patients (541 men; mean age 74 ± 11 years). Patients were retrospectively divided into three groups according to the level of the peak TRV at the time of enrolment in accordance with the current ESC and ERS guidelines 10 : Group 1 included patients with TRV < _2.8 m/s; Group 2 included patients with TRV between 2.9 m/s and 3.4 m/s and Group 3 included patients with TRV >3.4 m/s. Group 1 was used as reference. Group 3 was identified as the PH group. In a second analysis, patients were divided into two groups, comparing the PH group (Group 3) with the rest of the population (Group 1 and Group 2).
Methods

Patients
Baseline clinical and demographic characteristics including cardiovascular risk factors, presence of symptoms, comorbidity status, and presence of coronary artery disease (documented history of acute coronary syndromes, coronary revascularization or coronary artery disease previously confirmed by coronary angiography: reduction of the normal diameter > _50% in the left main coronary artery and > _70% in the right coronary, left anterior descending and circumflex arteries) were retrospectively recorded from medical charts. Blood pressure and heart rate were measured for all patients at the time of echocardiography. A comorbidity index summating the patient's individual comorbidities was calculated. 12 Echocardiographic data were collected prospectively, while clinical data and outcome data were retrospectively recorded.
Echocardiography
All patients underwent a comprehensive Doppler-echocardiographic study, using commercially available ultrasound systems. When patients were in sinus rhythm, 3 cardiac cycles were averaged for all measures. For patients in atrial fibrillation (AF), 5 cardiac cycles were averaged. Effective AVA was calculated by using the continuity equation. The LV outflow tract was measured in parasternal long-axis view with zoom on the aortic valve. LV outflow tract time-velocity integral was recorded in apical five-chamber view. Mean aortic valve gradient and peak aortic jet velocity were systematically measured in several acoustic windows (apical five chambers, right parasternal, suprasternal, and epigastric views) and the highest recorded value was taken into account. LV ejection fraction was measured by the Simpson biplane method. LV internal diameters and wall thickness were measured at end-diastole and end-systole in the 2D parasternal long-axis view 13 and LV mass was calculated using an anatomically validated formula. 14 Stroke volume was calculated by multiplying the LV outflow tract area by the LV outflow tract time velocity integral and cardiac output was calculated by multiplying stroke volume by heart rate. LA volume was measured in LV end-systole by the Simpson biplane method in apical two-and four-chamber views. 13 Standard practice in the echocardiography laboratories was to estimate the peak pulmonary artery systolic pressure (PASP) using the simplified Bernoulli equation PASP = 4 (peak TRV)2 þ right atrial pressure. However, for the purposes of this study and to eliminate the subjective bias associated with estimations of mean right atrial pressure, the severity of PH was assessed on the basis of the peak TRV recorded on any view.
Follow-up
Patients were followed by clinical consultations and echocardiography in the outpatient clinics of the two tertiary centres. A few patients were followed in public hospitals or private practices by referring cardiologists working in collaboration with the tertiary centres. Information on followup was obtained by direct patient interview and clinical examination and/ or by repeated follow-up letters, questionnaires, and telephone calls to physicians, patients, and (if necessary) next of kin. Median overall followup was 31 months. The study endpoint was overall survival after diagnosis starting at the baseline echocardiography. Institutional review board approval was obtained prior to conducting the study. The study was conducted in accordance with institutional policies, national legislation, and the revised declaration of Helsinki. All covariates associated with TRV >3.4 m/s (P < 0.10) on univariate were included in a multivariable logistic regression model to determine variables independently associated with TRV >3.4 m/s. Event rates ± 1 standard error of the three groups were estimated according to the Kaplan-Meier method and compared with two-sided logrank tests. Univariate and multivariate analyses of time to events were performed using Cox proportional hazards model with TRV as independent variable in categorical and continuous format. We entered in the model covariates considered to have a potential prognostic impact on an epidemiological basis. These covariates were: age, gender, New York Heart Association (NYHA) class, hypertension, history of atrial fibrillation, comorbidity index, chronic obstructive pulmonary disease (COPD), aortic valve area, coronary artery disease and LVEF (Model 1). The effect of aortic valve surgery on outcome was analysed as a time-dependent covariate in a second model (Model 2). Hazard ratios (HR) and 95% confidence intervals (CI) were estimated for all-cause mortality. Subgroup analyses (stratified by age < _ or > 70 years, sex, coronary artery disease, hypertension, NYHA class, atrial fibrillation and COPD) were conducted to determine the homogeneity of the association between high TRV (>3.4 m/s) and the outcome variable. First, we estimated the effect of TRV >3.4 m/s on the risk of overall mortality in each subgroup using a Cox univariate model and then we formally tested for first-order interactions in Cox models by entering interaction terms, separately for each subgroup. A P-value <0.05 was considered statistically significant. All Pvalues are the results of two-tailed tests.
Statistical analysis
Results
Clinical and echocardiographic parameters
Baseline demographic and clinical characteristics of the 1019 patients and the results of the comparison between Group 1 (n = 695, 68%), Group 2 (n = 212, 21%), and Group 3 (n = 112, 11%) are displayed in Table 1 . Compared with Group 1 patients, Group 3 patients had a higher frequency of NYHA class III to IV (P < 0.001), were older (P < 0.001) and more often women (P = 0.008). Compared with Group 1, hypertension (P = 0.014), diabetes (P = 0.048), history of atrial fibrillation (P < 0.001), and COPD (P = 0.001) were more frequent in Group 3. A higher frequency of NYHA class III to IV was observed in Group 2 patients compared to Group 1 patients (P = 0.003). Group 2 patients were significantly older (P = 0.001) compared with Group 1 patients. Compared with Group 1, hypertension (P = 0.018) and history of atrial fibrillation (P < 0.001) were more frequent in Group 2. There was no difference between the three groups in term of systolic blood pressure at the time of echocardiography. Compared with Group 1 patients, Group 2 and 3 patients had higher creatinine values (P = 0.005) and Euroscore II (P < 0.001). Dividing the whole population into two groups with a 3.4 m/s TRV cut-off (Table 3) , patients with PH were older (P = 0.008) had more severe symptoms (P < 0.001), more often a history of AF (P < 0.001) and associated COPD (P = 0.001).
Echocardiographic parameters are displayed in Table 2 . The three groups had similar AVA (P = 0.15), indexed AVA (P = 0.47), peak aortic jet velocity (P = 0.32) and transaortic mean pressure gradient (P = 0.15). Stroke volume index (P = 0.039) and LVEF (P = 0.001) were significantly lower in Group 3 than in Group 1. End-diastolic and systolic LV diameters (P = 0.002 and P < 0.001, respectively), LV mass index (P < 0.001), E/e' ratio (only available in 44% of patients) (P < 0.001) and left atrial volume index (P < 0.001) were higher in Group 3 than in Group 1.
All covariates associated with TRV >3.4 m/s (P < 0.10) on univariate analysis (age, sex, NYHA, hypertension, COPD, history of AF, comorbidities, LA volume, LVEF, and LV mass) were included in a multivariable logistic regression model to determine variables independently associated with TRV >3. 4 Dividing the whole population into two groups with a 3.4 m/s TRV threshold ( Table 3) , patients with PH had lower stroke volumes (P = 0.005) and LVEF (P = 0.016), greater LV diastolic and systolic diameters (P = 0.004 and P = 0.020, respectively) and indexed LV mass (P < 0.001), increased LV filling pressures (P < 0.001) and LA volume index (P < 0.001).
Clinical and echocardiographic characteristics of the 271 patients with no tricuspid regurgitation or without adequate Doppler signal of TR are displayed in Supplementary data online, Table S1 . Seventy four (27%) patients died in the group with no or inadequate TRV signal and 282 (28%) in the study population (161 in group 1 (23%), 74 in group 2 (35%), and 47 in group 3 (42%)).On multivariate analysis, the risk of death of patients with no or inadequate TRV signal was comparable to that of the study population (adjusted HR 0.98 [0.73-1.31], P = 0.88).
Outcome implication of TRV
Sixty eight patients were lost to follow-up (8%). During the study period, management was exclusively medical in 255 patients (25%), either because they were asymptomatic with no Class I or Class IIa indications for surgery, either because they refused aortic valve replacement (AVR) or because they were considered inoperable or at very high surgical risk before the emergence of transcatheter aortic valve replacement (TAVR) in our centres (i.e. 2011). Five balloon valvuloplasty procedures were performed as a palliative measure in this population. AVR (n = 684) and TAVR (n = 80) were performed in 764 patients (75%). Among surgical patients, aortic bioprostheses were used in 69% of cases (n = 527) and 176 patients (26%) underwent at least one associated coronary artery by-pass graft at the time of surgery. The impact of surgery on outcome was powerful (HR 0.50; 95% CI [0.41-0.62]; P < 0.001).
Univariate analysis TRV was strongly linked to mortality (HR 1.24 ; 95% CI [1.15-1.33] per 0.2 m/s increase; P < 0.01). Three-year survival was 87 ± 3% for patients with TRV < _2.8 m/s, 79 ± 7% for patients with TRV between 2.9 and 3.4 m/s and 70 ± 3% for patients with TRV >3.4 m/s (overall log rank P-value < 0.001) (Figure 1) . On univariate Cox analysis, Group 2 and Group 3 had higher mortality risk compared to Group 1 (both P < 0.001, Table 4 ). Dividing the whole population into two groups with a 3.4 m/s TRV threshold, 3-year survival was 82 ± 3% for patients with TRV < _3.4 m/s and 70 ± 3% for patients with (Figure 3 and Table 4 ) and after further adjustment for surgery (adjusted HR 1.22 [1.04- 1.42 ], P = 0.012) (see Supplementary data online, Figure S1 and Table 4 ). After adjustment, Group 1 and Group 2 had comparable outcome ( Figure 3 and Figure S2 ; The association between TRV >3.4 m/s and risk of death was consistent in subgroups of patients with AS (stratified by age, sex, coronary artery disease, hypertension, NYHA class, atrial fibrillation and COPD). We did not observe any interaction between the outcome impact of TVR >3.4 m/s and the adjustment variables (all P-values for interaction >0.10). Furthermore, there was no interaction (all P-values >0.10) between the prognostic impact of TVR >3.4 m/s and additional variables of adjustment (systolic blood pressure at the time of echocardiography, indexed left atrial volume, indexed stroke volume, and E/e' ratio).
In the two subgroups of patients with normal flow-high gradient AS and patients with low flow-low gradient AS, on multivariable analysis adjusted for surgery (treated as a time dependent variable), TRV > 3.4 m/s remained associated with poor prognosis (adjusted HR 1.58 
Discussion
This analysis of a large cohort of patients with severe AS patients shows the prognostic impact of PH based on TRV as recommended by current ESC guidelines (i.e. TRV >3.4 m/s). 10 Peak TRV >3.4 m/s . was an independent predictor of mortality during follow-up. After adjustment for age, gender, comorbidity, symptoms, atrial fibrillation, coronary artery disease, LVEF, and AVR, PH remained associated with an almost 1.5-fold increase in the risk of overall mortality. These data suggest that the baseline level of pulmonary pressure should be considered for clinical decision-making in patients with severe AS and preserved LVEF. Left heart disease, whether caused by left ventricular dysfunction or left-sided valvular disease, is the most common cause of PH. In aging Western populations, AS is now the most common acquired valvular heart disease. In AS, chronic pressure overload due to stenotic valve causes an increase in LV mass and consequently in chamber stiffness. The prevalence of PH in AS varies widely from 15 to 30%, depending on patient selection criteria and the threshold of pulmonary pressure used to define PH. 1, 7 We report lower frequency of patients with PH (11%) compared to previous studies. 1, 7 These studies did not exclude associated moderate or severe mitral regurgitation accounting for 27-53% of the population. 1, 7 This high proportion of mitral regurgitation may explain a higher prevalence of severe PH than in our study because we excluded patients with more than mild mitral regurgitation, which could have constituted a confounding bias. The use of current guidelines 10 to estimate pulmonary pressure may lead to a certain degree of underestimation, but most importantly avoids overestimation, given the inaccuracies of right atrial pressure estimation and amplification of measurement errors when derived variables are used. 10, 16 In severe AS, PH initially develops as a consequence of passive backwards transmission of filling pressures due to impaired left ventricular relaxation and distensibility. 17 A loss of left atrial compliance Impact of pulmonary hypertension can lead to and/or exacerbate PH. 18 Controversial results have been reported on the relationship between LVEF and PH in AS, as some studies reported only a weak correlation 19, 20 while others reported a more significant association with PH. 1, 21 Indeed, PH in severe AS can occur in the presence of normal LVEF 19 and a recent report suggests an association between decreased longitudinal systolic function and PH. 21 PH has been reported to be strongly correlated with elevated LV end-diastolic pressure. 5, 20, 22 A recent study 23 reported that, in most elderly subjects with invasively measured PH, PH is largely due to left heart congestion. Accordingly, in the present study, we identified left atrial (LA) size as determinant of PH at inclusion. LA remodelling may reflect chronic exposure to abnormal filling pressures, secondary to either severe AS alone or, more frequently, as a result of concomitant hypertension, diabetes or aging. Diastolic dysfunction can occur independently of the severity of AS. 19 Weak correlations between aortic valve area and PASP have been reported in both severe 2, 20 and moderate-to-severe AS. 19 Just as PH is not always present in critically severe AS, superimposed diastolic dysfunction can induce PH in the presence of moderate AS. 19 Rapid reduction in pulmonary artery pressure in AS, after AVR, particularly in patients with severe PH 4, 24 has been reported, resulting in improvement in clinical status. 5, 24 However, multiple and intricate pathogenic mechanisms may be involved in PH in AS. In some patients, additional factors, such as endothelial dysfunction and vasoconstriction and/or vascular remodelling can lead to further increases in vascular resistance and consequently elevated pulmonary artery pressure. 17 These changes might lead to pulmonary vascular disease, increased right ventricle (RV) afterload, and RV failure, 18 consequently jeopardizing the reversibility of PH after surgery, 21 leading to impaired long-term outcome.
Our results indicate an excess mortality in patients with severe AS and PH, after adjustment for covariates of prognostic importance. Previous studies have reported poor prognosis for patients with severe AS and severe PH (TRV > _4 m/s) treated conservatively and potential benefit of surgery despite increased perioperative risk. 4 In a recent retrospective study, 8 operative mortality was nearly twice as high (9% vs. 5%) in the presence of PH, defined by systolic pulmonary pressure >60 mmHg, but more than 70% of patients in the PH group had severe symptoms. Patients in this study 8 were more symptomatic than the patients in our study, and the authors did not adjust their results to the presence of COPD. In addition, increased rates of inhospital adverse events (post-operative acute renal failure, heart failure or in-hospital mortality) were observed in patients with severe PH who underwent AVR. After AVR, long-term survival appeared to be lower in patients with PH. 6, 8 An increased 30-day and 1-year mortality in patients with PH (PASP >50 mmHg) before TAVR has been reported in recent studies, 25 but 18.4% of patients in the PH group had moderate or severe mitral regurgitation. Another study 26 suggested that persistence of severe PH after TAVR was an even stronger predictor of 1-year mortality than baseline severe PH. These results are consistent with previous cardiac catheterization-based studies. 5 Such patients selected for TAVR have an advanced age and often more comorbidities, which may also induce PH, such as hypertension, renal insufficiency or sleep apnoea. Compared to the patients of Testa et al., 26 our patients were younger (mean age of 74 vs.
81
) and less severely symptomatic as only 49% of our patients were in NYHA class III or IV compared to 88% in Testa et al. 26 These data suggest that the onset of PH in these older patients may often coincide with the appearance of frank symptoms, consequently leading to AVR. Whereas echocardiographic data were collected prospectively, clinical and outcome data were obtained by review of medical records. Our study therefore presents the limitations inherent to retrospective analyses. Patients with more than mild MR or with severe TR were excluded so we could not investigate the impact of PH in this population. Cardiologists with expertise in valvular heart disease performed diagnosis and follow-up and surgical decisions were taken in accordance with practice guidelines (Class I or Class IIa indications) by the heart team with the approval of the patient's physician. Our study is not a PH prevalence study because patients were recruited in echocardiography laboratories.
This study demonstrates the negative prognostic impact of PH, as assessed by current ESC/ERS guidelines using echocardiography, on long-term survival of patients with severe AS, irrespective of functional status, COPD and AVR. Baseline TRV should therefore be systematically evaluated by echocardiography and should be taken into account for the management of severe AS.
